Daniel Morgensztern, MD

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

Daniel Morgensztern, MD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the monumental impact that immunotherapy has had on the field of non–small cell lung cancer (NSCLC).